Tempo Therapeutics, Inc. — SEC Form D Filing

Tempo Therapeutics, Inc. filed an SEC Form D on September 11, 2026, reporting $14.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 11, 2026
Amount reported
$14.00M
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://www.tempothera.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

There is a gap in surgical oncology, and patients undergoing soft tissue reconstructions for dermal and abdominal wall indications face significant clinical challenges.

Solution

Tempo Therapeutics is developing novel biosurgery products using MAP technology that build new vascular tissue within patients to improve tissue strength and restore function.

Why now

Advances in tissue engineering, immunomodulation, and material science are enabling new approaches to regenerative medicine and biosurgery that were not previously possible.

Verdict

This cleared because investors prioritized a novel biological platform's potential in a challenging surgical domain, not because of immediate market traction or a proven commercialization path. They were implicitly betting on the underlying MAP technology’s ability to unlock new vascularization outcomes for high-need surgical repairs, accepting a long development and regulatory timeline. The limited upside stemmed from the inherent capital intensity and regulatory hurdles of medical device and biotech innovation, requiring substantial follow-on rounds to realize value.

Source: SEC EDGAR Form D filing